Filing Details

Accession Number:
0001415889-25-000536
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-01-03 17:04:12
Reporting Period:
2024-12-31
Accepted Time:
2025-01-03 17:04:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1620463 Athira Pharma Inc. ATHA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1604834 James Mark Litton C/O Athira Pharma, Inc.
18706 North Creek Parkway, Suite 104
Bothell WA 98011
President And Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-12-31 108,333 $0.00 267,698 No 4 M Direct
Common Stock Disposition 2025-01-02 25,107 $0.56 242,591 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-12-31 108,333 $0.00 108,333 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
216,667 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 6,563 Indirect By Irrevocable Trust of OSL
Common Stock 6,563 Indirect By Irrevocable Trust of SWL
Common Stock 6,563 Indirect By Irrevocable Trust of WGL
Footnotes
  1. Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person.
  2. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.5414 to $0.5939, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  3. Reflects Common Stock held by Irrevocable Trust of OSL held for the benefit of Dr. Litton's children.
  4. Reflects Common Stock held by Irrevocable Trust of SWL held for the benefit of Dr. Litton's children.
  5. Reflects Common Stock held by Irrevocable Trust of WGL held for the benefit of Dr. Litton's children.
  6. RSUs convert into common stock on a one-for-one basis.
  7. Each RSU represents a contingent right to receive one (1) share of Issuer's common stock.
  8. On October 3, 2024, the reporting person was granted 325,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates.